CG Oncology, Inc.
No enriched coverage for $CGON in the last 7 days.
CG Oncology (CGON) shareholder Ambaw Bellete plans to sell 5,789 shares via option exercise, with Morgan Stanley facilitating. The sale is part of ongoing secondary market activity, not a new issuance, and is set to close by August 27, 2026, according to a Rule 144 filing.
CG Oncology, a $7B biotech firm, moved its HQ from Irvine to Dallas, citing business benefits. The company, listed on Nasdaq, focuses on bladder cancer treatments.
CG Oncology (CGON) officer Ambaw Bellete filed a Form 144 notice to sell 5,762 shares of common stock, following a stock option exercise. Bellete has sold significant shares in recent months, including 100,000 shares on August 19, 2026, for $7.95M. Morgan Stanley Smith Barney LLC is the broker.
Recent CGON coverage spans financial news, insider activity and earnings.
In the last 30 days, CGON insiders filed 1 SEC Form 4 transaction — no purchases and 1 sale ($75K). The most active reporter was POST LEONARD E with 1 filing. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
Minor secondary market sale; unlikely to move price materially.
The move may affect operational costs and local market perception but has limited immediate price impact.
Potential modest increase in share supply could pressure price in the short term.
Near-term trading focus is on progress toward PIVOT-006 topline and the planned BLA submission for HR BCG-unresponsive NMIBC in 4Q26, plus cash runway into 2029.
The filing is a catalyst mix: cash runway visibility supports funding confidence, while multiple clinical and regulatory milestones (PIVOT-006 topline soon, BLA completion 4Q’26) set near-term event risk.
alphai scores every news story that mentions CGON with an AI model for sentiment and relevance, and aggregates insider trades from CG Oncology, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
CG Oncology (CGON) shareholder Ambaw Bellete plans to sell 5,789 shares via option exercise, with Morgan Stanley facilitating. The sale is part of ongoing secondary market activity, not a new issuance, and is set to close by August 27, 2026, according to a Rule 144 filing.
1 min readCG Oncology, a $7B biotech firm, moved its HQ from Irvine to Dallas, citing business benefits. The company, listed on Nasdaq, focuses on bladder cancer treatments.
1 min readCG Oncology (CGON) officer Ambaw Bellete filed a Form 144 notice to sell 5,762 shares of common stock, following a stock option exercise. Bellete has sold significant shares in recent months, including 100,000 shares on August 19, 2026, for $7.95M. Morgan Stanley Smith Barney LLC is the broker.
1 min readCG Oncology (NASDAQ: CGON) reported Q2 2026 results for the quarter ended June 30, 2026, with net loss of $79.1 million, or $0.90 per share. Cash, cash equivalents and marketable securities were about $1.0 billion, funding operations through 2029. The company said PIVOT-006 topline data are expected soon, and a BLA for HR BCG-unresponsive NMIBC is expected in Q4 2026.
6 min readCG Oncology, Inc. (CGON) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 CG Oncology Reports Second Quarter 2026 Financial Results and Provides Business Updates • PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy as an adjuvant therapy in intermediate-risk NMIBC anticipated in the near-term • BLA completion for HR BCG-u
4 min readMulay James sold 24,165 shares of CG Oncology, Inc. (CGON) at $75.16 ($1.82M total) on 2026-07-10 under a Rule 10b5-1 trading plan.
1 min readTipRanks highlights two stocks with large recent insider purchases. CG Oncology (CGON): board member Brian Guan-Chyun Liu bought 371,085 shares (~$24.8M) on June 25; company has ~$1.1B cash and expects BLA submission in 4Q26. JPMorgan rates CGON Overweight with $96 target. Adobe (ADBE): director David Ricks bought 10,000 shares (~$1.95M) on June 25 amid a shift to a freemium model.
6 min readLiu Brian Guan-Chyun purchased 371,085 indirectly-held shares of CG Oncology, Inc. (CGON) at $66.87 ($24.81M total) on 2026-06-25 under a Rule 10b5-1 trading plan.
2 min readCG Oncology, Inc. (CGON) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. 8-K false 0001991792 0001991792 2026-06-04 2026-06-04 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 4, 2
2 min readPOST LEONARD E sold 1,000 shares of CG Oncology, Inc. (CGON) at $54.50 on 2026-06-04 under a Rule 10b5-1 trading plan.
1 min read
